To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Completed

• Conditions: Nasopharyngeal Carcinoma
• Interventions: Radiation: modified reduce-volume target IMRT

• Registration Number: NCT04387266
• Lead Sponsor: Fujian Cancer Hospital

Brief Summary

This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-05-10
• Study First Submitted QC: 2020-05-11
• Study First Posted: 2020-05-13
• Study Start: 2020-06-01
• Primary Completion: 2020-08-01
• Status Verified: 2020-10
• Study Completion: 2020-10-01
• Last Update Submitted: 2020-10-07
• Last Update Posted: 2020-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 471

Inclusion Criteria

1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT;
3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;
4. Diagnosis time: November 1, 2014 to December 31 , 2017

Read More

Exclusion Criteria

1. Disease progression during IMRT;
2. Previous malignancy or other concomitant malignant diseases;
3. The evaluation information of tumor efficacy can not be obtained;
4. Receive blind treatment in other clinical research.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Modified reduce-volume target IMRT	modified reduce-volume target IMRT	Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT

Primary Outcome Measures

Name	Time	Method
Local failure-free survival (LFFS)	60 month	The duration of time to LFFS was calculated from the date of histological diagnosis until documented treatment local failure.

Trial Locations

Locations (1)

Department of radiation oncology, Fujian cancer hospital; 🇨🇳 Fuzhou, Fujian, China